485 related articles for article (PubMed ID: 11038485)
1. Chemiluminometric determination of tissue polypeptide antigen (TPA), cancer antigen 15-3 (CA 15-3), carcinoembryonic antigen (CEA) in comparison with vascular endothelial growth factor (VEGF) in follow-up of breast cancer.
Findeisen R; Albrecht S; Richter B; Deutschmann K; Zimmermann T; Distler W
Luminescence; 2000; 15(5):283-9. PubMed ID: 11038485
[TBL] [Abstract][Full Text] [Related]
2. Comparison of tissue polypeptide antigen (TPA) with cancer antigen 15-3 (CA 15-3) and carcinoembryonic antigen (CEA) in follow-up of breast cancer.
Findeisen R; Albrecht S; Richter B; Deutschmann K; Distler W
Clin Chem Lab Med; 1998 Nov; 36(11):841-6. PubMed ID: 9877089
[TBL] [Abstract][Full Text] [Related]
3. Vascular endothelial growth factor (VEGF)--a valuable serum tumour marker in patients with colorectal cancer?
Broll R; Erdmann H; Duchrow M; Oevermann E; Schwandner O; Markert U; Bruch HP; Windhövel U
Eur J Surg Oncol; 2001 Feb; 27(1):37-42. PubMed ID: 11237490
[TBL] [Abstract][Full Text] [Related]
4. Tumor markers in breast cancer monitoring should be scheduled according to initial stage and follow-up time: a prospective study on 859 patients.
Gion M; Peloso L; Mione R; Vignati G; Fortunato A; Saracchini S; Biasioli R; Gulisano M; Cappelli G
Cancer J; 2001; 7(3):181-90. PubMed ID: 11419026
[TBL] [Abstract][Full Text] [Related]
5. Serum vascular endothelial growth factor in breast cancer: its relation with cancer type and estrogen receptor status.
Heer K; Kumar H; Read JR; Fox JN; Monson JR; Kerin MJ
Clin Cancer Res; 2001 Nov; 7(11):3491-4. PubMed ID: 11705867
[TBL] [Abstract][Full Text] [Related]
6. Intensive post-operative follow-up of breast cancer patients with tumour markers: CEA, TPA or CA15.3 vs MCA and MCA-CA15.3 vs CEA-TPA-CA15.3 panel in the early detection of distant metastases.
Nicolini A; Tartarelli G; Carpi A; Metelli MR; Ferrari P; Anselmi L; Conte M; Berti P; Miccoli P
BMC Cancer; 2006 Nov; 6():269. PubMed ID: 17116247
[TBL] [Abstract][Full Text] [Related]
7. Relationship between tumor markers CEA and CA 15-3, TNM staging, estrogen receptor rate and MIB-1 index in patients with pT1-2 breast cancer.
Lumachi F; Basso SM; Brandes AA; Pagano D; Ermani M
Anticancer Res; 2004; 24(5B):3221-4. PubMed ID: 15510614
[TBL] [Abstract][Full Text] [Related]
8. Plasma vascular endothelial growth factor is useful in assessing progression of breast cancer post surgery and during adjuvant treatment.
Wu Y; Saldana L; Chillar R; Vadgama JV
Int J Oncol; 2002 Mar; 20(3):509-16. PubMed ID: 11836562
[TBL] [Abstract][Full Text] [Related]
9. Prognostic significance of serum Her2/neu, BCL2, CA15-3 and CEA in breast cancer patients: a short follow-up.
Samy N; Ragab HM; El Maksoud NA; Shaalan M
Cancer Biomark; 2010; 6(2):63-72. PubMed ID: 20571232
[TBL] [Abstract][Full Text] [Related]
10. Serum leptin, prolactin and vascular endothelial growth factor (VEGF) levels in patients with breast cancer.
Coskun U; Günel N; Toruner FB; Sancak B; Onuk E; Bayram O; Cengiz O; Yilmaz E; Elbeg S; Ozkan S
Neoplasma; 2003; 50(1):41-6. PubMed ID: 12687277
[TBL] [Abstract][Full Text] [Related]
11. Circulating vascular endothelial growth factor in patients with colorectal cancer.
Fujisaki K; Mitsuyama K; Toyonaga A; Matsuo K; Tanikawa K
Am J Gastroenterol; 1998 Feb; 93(2):249-52. PubMed ID: 9468253
[TBL] [Abstract][Full Text] [Related]
12. The pretreatment plasma level and diagnostic utility of M-CSF in benign breast tumor and breast cancer patients.
Ławicki S; Szmitkowski M; Wojtukiewicz M
Clin Chim Acta; 2006 Sep; 371(1-2):112-6. PubMed ID: 16631152
[TBL] [Abstract][Full Text] [Related]
13. Long-term follow-up study in breast cancer patients using serum tumor markers CEA and CA 15-3.
Lumachi F; Brandes AA; Boccagni P; Polistina F; Favia G; D'Amico DF
Anticancer Res; 1999; 19(5C):4485-9. PubMed ID: 10650797
[TBL] [Abstract][Full Text] [Related]
14. The correlation between immunohistochemically-detected markers of angiogenesis and serum vascular endothelial growth factor in patients with breast cancer.
Lantzsch T; Hefler L; Krause U; Kehl A; Goepel C; Koelbl H; Dunst J; Lampe D
Anticancer Res; 2002; 22(3):1925-8. PubMed ID: 12168895
[TBL] [Abstract][Full Text] [Related]
15. Serum vascular endothelial growth factor is often elevated in disseminated cancer.
Salven P; Mänpää H; Orpana A; Alitalo K; Joensuu H
Clin Cancer Res; 1997 May; 3(5):647-51. PubMed ID: 9815732
[TBL] [Abstract][Full Text] [Related]
16. Comparison of TPS with CEA and CA 15.3 in follow-up of Chinese breast cancer patients.
Hu XC; Day W; Jones B; Loo WT; Chow LW
Anticancer Res; 2002; 22(3):1865-8. PubMed ID: 12168883
[TBL] [Abstract][Full Text] [Related]
17. [Clinical importance of determination of tumor markers during follow-up in breast carcinoma].
Fínek J; Holubec L; Topolcan O; Pikner R; Sůvová B; Treska V
Cas Lek Cesk; 2004; 143(3):174-7. PubMed ID: 15134036
[TBL] [Abstract][Full Text] [Related]
18. A re-evaluation of carcinoembryonic antigen (CEA) as a serum marker for breast cancer: a prospective longitudinal study.
Guadagni F; Ferroni P; Carlini S; Mariotti S; Spila A; Aloe S; D'Alessandro R; Carone MD; Cicchetti A; Ricciotti A; Venturo I; Perri P; Di Filippo F; Cognetti F; Botti C; Roselli M
Clin Cancer Res; 2001 Aug; 7(8):2357-62. PubMed ID: 11489813
[TBL] [Abstract][Full Text] [Related]
19. Circulating levels of vascular endothelial growth factor in patients with oral squamous cell carcinoma.
Shang ZJ; Li JR; Li ZB
Int J Oral Maxillofac Surg; 2002 Oct; 31(5):495-8. PubMed ID: 12418564
[TBL] [Abstract][Full Text] [Related]
20. [Significance of combined determination of CK19mRNA, carcinoembryanic antigen, neuron-specific enolase, and tissue polypeptide antigen in peripheral blood of patients with lung cancer].
Pan QR; Zhang X; Xu ZF; Zheng S
Ai Zheng; 2002 Feb; 21(2):196-9. PubMed ID: 12479076
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]